|
|
|
|
Phase III Study Showed Lucentis Improved Vision In Patients With Branch Retinal Vein Occlusion
Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Phase-III study shows Lucentis improves vision in branch retinal vein occlusion
Roche announced that the phase-III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with ...
|
|
|
Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Clinical and Experimental Ophthalmology, 07/02/09 Print Save in My Library Free Abstract Maca SM et al.- IVTA might be considered as a treatment for...
|
|
|
Genentech's Phase III retinal vein occlusion trial meets endpoint
(Datamonitor via COMTEX) -- DNA | Quote | Chart | News | PowerRating -- Genentech, a biotechnology company, has reported that the Phase III study Bravo showed Lucentis improved vision, as measured by the primary endpoint of mean change from...
|
|
|
FDA approves implant for macular edema associated with RVO
Source: Ophthalmology Times E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License Irvine, CAThe FDA has approved dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) for the treatment of macular edema...
|
|
|
Jul 2, 2009
-- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
UPDATE 1-Roche's Lucentis found to curb retinal occlusion
LOS ANGELES, July 2 (Reuters) - Monthly injections of Roche Holding AG's Lucentis can significantly improve sight in people with retinal vein occlusion, which leads to vision loss, according to research released by the company's Genentech...
|
|
|
Genentech says Lucentis succeeded late stage trial
Genentech says Lucentis injections improved vision for patients with macular edema Buzz up!Companies: SOUTH SAN FRANCISCO, Calif! (AP) -- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its...
|
|
|
Genentech says Lucentis injections improved vision for patients with macular edema
SOUTH SAN FRANCISCO, Calif.(AP) - Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema. Lucentis is approved to...
|
|
|
Genentech says Lucentis met goal in clinical trial
Genentech says Lucentis injections improved vision for patients with macular edema Buzz up!Companies: SOUTH SAN FRANCISCO, Calif! (AP) -- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its...
|
|
|
Genentech says Lucentis succeeded late stage trial
SOUTH SAN FRANCISCO, Calif.(AP) -- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema. Lucentis is approved to...
|
|
|
Genentech says Lucentis succeeded late stage trial
SOUTH SAN FRANCISCO, Calif.- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein...
|
|
|
Genentech says Lucentis met goal in clinical trial
SOUTH SAN FRANCISCO, Calif.- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein...
|
|
|
Genentech says Lucentis met goal in clinical trial
SOUTH SAN FRANCISCO, Calif.(AP) -- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein...
|
|
|
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
VANCOUVER, July 2 /CNW/ - iCo Therapeutics Inc.(TSX-V: ICO) today announced that iCo-007, iCo's lead Diabetes Macular Edema candidate, has been featured in an article in the Journal of Diabetes Science and Technology, a peer...
|
|
|
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
VANCOUVER, July 2 /CNW/ - iCo Therapeutics Inc.(TSX-V: ICO) today announced that iCo-007, iCo's lead Diabetes Macular Edema candidate, has been featured in an article in the Journal of Diabetes Science and Technology, a peer...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- BRAVO evaluated the safety and efficacy of six monthly injections of Lucentis compared to monthly sham injections.The two doses of Lucentis studied showed a statistically significant improvement in best-corrected visual acuity (the...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Companies mentioned in this article: Genentech, Inc.SOUTH SAN FRANCISCO, Calif. -- (BUSINESSWIRE) -- Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured...
|
|
|
Roche's Lucentis found to curb retinal occlusion
ROCHE/LUCENTIS (UPDATE 1):UPDATE 1- * Six monthly doses of Lucentis evaluated * Lucentis already approved for macular degeneration LOS ANGELES (Reuters) - Monthly injections of Roche Holding ( RHHBY.PK - news - people ) AG's Lucentis...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
UPDATE 1-Roche's Lucentis found to curb retinal occlusion
* Six monthly doses of Lucentis evaluated * Lucentis already approved for macular degeneration LOS ANGELES, July 2 (Reuters) - Monthly injections of Roche Holding AG's (ROG.VX) Lucentis can significantly improve sight in people with...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch R
Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
BusinessWire - Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Study Showed Early and Sustained Improvement in Vision Through Six Months -- ) SOUTH SAN FRANCISCO, Calif., Jul 02, 2009 (BUSINESS WIRE) -- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best...
|
